Cell and tissue models containing fibroblasts at the dermal-subcutaneous junction and their applications
By using a dermal-subcutaneous fibroblast model, combined with gene expression level identification and specific culture methods, the problem of insufficient sensitivity in existing models has been solved, enabling effective fibroblast differentiation and active agent screening, which is suitable for skin aging research and screening of anti-aging active agents.
Patent Information
- Application Number
- CN201980042828.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-06-29
- Filing Date
- 2019-07-01
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2039-07-01
AI Technical Summary
Existing fibroblast models lack sensitivity when screening for active agents, are prone to false negatives, and cannot effectively promote the differentiation of fibroblasts into adipocytes, osteoblasts, and chondrocytes.
Fibroblasts from the dermal-subcutaneous junction (DHJF fibroblasts) were used to identify these cells by the expression levels of genes UCP2, ACAN, FGF9, and COL11A1, as well as the expression product level of KLF9. These cells were then cultured on 2D culture supports or collagen sponges using specific culture methods to prepare cell and tissue models.
It improves the sensitivity of the fibroblast model, enabling effective screening of active agents that promote fibroblast differentiation into adipocytes, osteoblasts, and chondrocytes, avoiding false negative results, and is suitable for skin aging research and screening of anti-aging active agents.
Smart Images

Figure BDA0002857044030000171 
Figure BDA0002857044030000181 
Figure BDA0002857044030000182
Abstract
Description
[0001] The present invention relates to novel cell models and tissue models comprising fibroblasts at the dermal-subcutaneous junction, and also to methods for preparing the same.
[0002] Furthermore, the present invention relates to the use of these models as tools for screening active agents that promote the differentiation of fibroblasts into adipocytes, osteoblasts and / or chondroblasts.
[0003] The skin consists of three connected compartments: the epidermis, dermis, and subcutaneous tissue.
[0004] The epidermis is mainly composed of three cell types, namely keratinocytes (which make up the majority of the cells in the epidermis), melanocytes and Langerhans cells. These cells form the cornified epithelium, which is differentiated into overlapping layers, which are topped by a layer of dead cells forming the stratum corneum.
[0005] The subcutaneous tissue is composed of lipid lobules, formed by adipocytes, surrounded by connective trabeculae. These connective trabeculae stabilize the tissue's cohesion while facilitating the passage of blood vessels. The main function of the subcutaneous tissue is to ensure thermal regulation of the body, while also providing storage for energy molecules and toxins.
[0006] The epidermis and subcutaneous tissue surround the dermis. The subcutaneous tissue provides a firm support for the epidermis and also serves as a nutritional component for the epidermis. The subcutaneous tissue is primarily composed of fibroblasts and extracellular matrix.
[0007] Fibroblasts, also commonly called "supporting cells," are found in many connective tissues, particularly skin, tendons, cartilage, bone tissue, etc.
[0008] Currently, only two subpopulations of fibroblasts in the skin have been identified in the literature: papillary fibroblasts and reticular fibroblasts.
[0009] The potential of fibroblasts as a screening tool was highlighted by in vitro studies showing their ability to differentiate into other cell types that form connective tissue, such as fat cells (adipocytes), cartilage cells (chondroblasts), and bone cells (osteoblasts).
[0010] Thus, models have been described in the literature that allow screening of agents that promote the differentiation of fibroblasts into adipocytes, chondroblasts and / or osteoblasts. Of particular note are: Brun C et al. "Intrinsically aged dermal fibroblasts fail to differentiate into adipogenic lineage" Exp Dermatol. 2016 Nov 25 (11): 906-909; Chen FG et al. "Clonal analysis of nestin(-)vimentin(+)multipotent fibroblasts isolated from human dermis", J Cell Sci. 2007 Aug 15 120(Pt 16): 2875-83; Jeney F et al. "Cytochemical studies on the fibroblast-preadipocyte relationships in cultured fibroblast cell [Cytochemical studies on the fibroblast-preadipocyte relationship in cultured fibroblast cell lines]" Acta Histochem. 2000 Nov;102(4):381-9.
[0011] In addition to its use in studying the differentiation capacity of fibroblasts, such a model has also been shown to be useful in the study of skin aging. Indeed, skin aging is known to be associated with a loss of the ability of fibroblasts to differentiate into adipocytes (Cécilia Brun et al. "Altération de la différenciation adipogénique des fibroblastesdermiques avec “Alteration in the adipogenic differentiation of dermal fibroblasts with age”, Annales de Dermatologie et Vénérologie [Annals of Dermatology], vol. 143, December 2016).
[0012] However, these models have proven to be insufficiently efficient, and in particular insufficiently sensitive, as they can produce false negatives for active agents as shown in the comparison below.
[0013] Therefore, there remains a need to provide more efficient and / or sensitive cell or tissue models that avoid false negatives in methods for screening agents that promote the differentiation of fibroblasts into adipocytes, osteoblasts and / or chondroblasts.
[0014] The applicant has demonstrated that the use of specific dermal fibroblasts, i.e., a subpopulation of fibroblasts at the dermal-subcutaneous junction, makes it possible to obtain cell or tissue models that are more sensitive than the models disclosed in the prior art (these cell or tissue models promote the differentiation of fibroblasts into adipocytes, chondroblasts and / or osteoblasts) and, in particular, avoid false negatives caused by an excessive proportion of non-responsive cells of the papillary and / or reticular fibroblast types.
[0015] Therefore, a first subject of the present invention is an in vitro method for preparing a cell model, comprising at least one step of culturing fibroblasts of the dermal-subcutaneous junction.
[0016] The present invention also relates to an in vitro method for preparing a tissue model, comprising at least one step of culturing fibroblasts of the dermal-subdermal junction on a collagen sponge.
[0017] According to another of its subjects, the present invention relates to cell and tissue models obtained by said method.
[0018] The present invention also relates to methods for screening active agents that promote differentiation of fibroblasts at the dermal-subcutaneous junction into adipocytes, osteoblasts and / or chondroblasts using the cell and tissue models. DETAILED DESCRIPTION
[0019] fibroblasts at the dermal-subcutaneous junction
[0020] "Fibroblasts of the dermal-subcutaneous junction" or "DHJF fibroblasts" herein refer to fibroblasts located in the region of the connective trabeculae extending from the dermis into the subcutaneous layer. Cultured DHJF fibroblasts typically have a highly heterogeneous morphology. Thus, highly diverse forms can be observed in cell layers ranging from very small tricuspid cells to very large multipolar cells with a highly distinct intracellular trabecular network (visible under a light microscope).
[0021] In addition to their morphological characteristics and location as described above, fibroblasts at the dermal-subcutaneous junction according to the present invention can be identified by measuring the expression level of at least one gene selected from the group consisting of genes UCP2, ACAN, FGF9 and COL11A1, and measuring the level of the expression product of gene KLF9.
[0022] In particular, the method for identifying fibroblasts as dermal-subdermal junction fibroblasts comprises:
[0023] a) providing a biological sample comprising at least one dermal fibroblast,
[0024] b) measuring the level of an expression product of at least one gene selected from the group consisting of genes UCP2, ACAN, FGF9 and COL11A1, and measuring the level of an expression product of gene KLF9 in the biological sample provided in step a),
[0025] c) identifying the dermal fibroblasts in step a) as dermal-subdermal junction fibroblasts when:
[0026] 1) (i) the level of expression product of gene UCP2 is decreased relative to the control level,
[0027] (ii) the level of the expression product of the gene ACAN increases relative to the control level,
[0028] (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and / or
[0029] (iv) the level of the expression product of the gene COL11A1 increases relative to the control level,
[0030] as well as
[0031] 2) The expression level of the KLF9 gene product increased relative to the control level,
[0032] The control levels of 1(i), 1(ii), 1(iii) and 1(iv) are preferably the levels of the expression products of the genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, respectively, and the control level of 2) is preferably the level of the expression product of the gene KLF9 in dermal fibroblasts known to be reticular fibroblasts.
[0033] Advantageously, the biological sample provided in step a) is an in vitro culture of dermal fibroblasts or a mixture of dermal fibroblasts, a sample derived from a skin biopsy, or a sample derived from dermis or skin equivalent obtained in vitro.
[0034] Preferably, a biological sample of dermal fibroblasts is isolated from non-defatted human skin at the connective trabeculae present at the dermal-subcutaneous junction.The connective trabeculae are removed using forceps and scissors.
[0035] In particular, the sample originates from a human skin biopsy performed on a young subject (eg a subject between the ages of 15 and 40, preferably between the ages of 17 and 31).
[0036] "The expression product of gene X" herein refers to the mRNA encoded by the gene X or the protein encoded by the gene X. Thus, the level of the expression product of gene X can be measured by quantifying the corresponding mRNA or protein. In a specific embodiment, the expression product of gene X is the mRNA encoded by the gene X.
[0037] Preferably, the level of expression product corresponds to the concentration or amount of expression product.
[0038] When the ratio [expression level of gene X in the test sample / control level of gene X] is greater than or equal to 2, the level of the expression product of gene X in the test sample is considered to be increased.
[0039] When the ratio [control level of gene X / expression level of gene X in the test sample] is greater than or equal to 2, the level of the expression product of gene X in the test sample is considered to be decreased.
[0040] When the ratio [control level of gene X / expression level of gene X in the test sample] is greater than or equal to 2, a sign (-) is placed before the obtained value.
[0041] This ratio is often referred to as the "fold change."
[0042] "Control level" herein means a reference value, preferably corresponding to the level of said expression product of a gene in dermal fibroblasts derived from the same donor, known to be papillary or reticular dermal fibroblasts.
[0043] "Dermal fibroblasts known to be papillary or reticular dermal fibroblasts" means herein that the type of dermal fibroblasts (papillary or reticular) has been determined based on their morphology, origin or detected biomarkers.
[0044] Specifically, dermal fibroblasts known to be papillary or reticular dermal fibroblasts are obtained as follows:
[0045] a) Papillary fibroblasts (Fp) and reticular fibroblasts (Fr) were isolated from undelipidated human skin.
[0046] b) Fr separation is performed on a portion of the tissue, thereby discarding its dermal-subcutaneous junction, and then the tissue is desquamated to 700 μm. Only the lower part of the tissue is retained; and or
[0047] c) Isolation of Fp was performed on tissue that had been sliced to 300 μm and de-epidermized after treatment with dispase (Roche - 2.4 units / ml) at 4° C. for 16 h.
[0048] The level of the expression product of gene X can be measured by any technique well known to those skilled in the art using step (b) of the above identification method. In particular, when the expression product is a protein, the level of the expression product can be measured by immunological assays such as ELISA assays, immunofluorescence assays (IFA), radioimmunoassays (RIA), competitive binding assays or Western blots. When the expression product is mRNA, the level of the expression product can be measured by RT-PCR, qRT-PCR, ddPCR (droplet digital PCR), by sequencing, such as by NGS-type sequencing (next generation sequencing) or by ddSEQ. TM Measured by single-cell isotype sequencing.
[0049] "Dermal fibroblast" herein means any fibroblast derived from the dermis.
[0050] "Papillary fibroblasts" herein refers to fibroblasts of the papillary dermis, which is characterized by a relatively thin extracellular matrix, a high cell density, and an organizational location between the epidermis and the superficial plexus, also known as the subpapillary web. Cultured papillary fibroblasts typically have a thin, spindle-shaped morphology.
[0051] "Reticular fibroblasts" herein refers to fibroblasts of the reticular dermis, which is characterized by a dense network of matrix fibers and a low cell density. At the tissue level, it extends from the superficial plexus to the deep plexus, also known as the dermal plexus. Cultured reticular fibroblasts typically have an elongated and more square appearance.
[0052] "Gene UCP2" herein refers to the gene encoding "mitochondrial uncoupling protein 2." Gene UCP2 is also known as gene SLC25A8, and protein UCP2 is also known as UCPH or "solute carrier family 25 member 8." It belongs to the mitochondrial anion carrier protein (MACP) family and is a protein that controls mitochondrial-derived reactive oxygen species. It is typically described in Pecqueur et al. (1999) Biochemical and Biophysical Research Communications 255:40-46. The human UCP2 protein sequence is typically cited by UniProt number P55851.
[0053] "Gene ACAN" herein refers to the gene encoding "aggrecan core protein." The gene ACAN is also known as the genes AGC1, CSPG1, and MSK16, and the ACAN protein is also known as "aggrecan," "cartilage-specific proteoglycan core protein," or CSPCP, or "chondroitin sulfate proteoglycan core protein 1," or "chondroitin sulfate proteoglycan 1." It is part of the extracellular matrix in cartilage tissue. It is a proteoglycan. It is typically described in Doege et al. (1991) J. Biol. Chem. 15:894-902. The human ACAN protein sequence is typically referenced by UniProt number P16112.
[0054] "Gene FGF9" herein refers to the gene encoding fibroblast growth factor 9. The protein FGF9 is also known as "glial activating factor" or GAF or "heparin-binding growth factor 9" or HBGF-9. It has a growth-stimulating effect on cultured glial cells. It is typically described in Miyamoto et al. (1993) Molecular and Cellular Biology 13:4251-4259. The human FGF9 protein sequence is typically referenced by UniProt accession number P31371.
[0055] "Gene COL11A1" herein refers to the gene encoding the α1(XI) collagen chain. Gene COL11A1 is also known as gene COLL6. This chain is one of the two α chains of type XI collagen, a minor fibrillar collagen. It is typically described in Yoshioka et al. (1990) J. Biol. Chem. 15:6423-6426. The human COL11A1 protein sequence is typically referenced by UniProt accession number P12107.
[0056] "Gene KLF9" herein means the gene encoding "Krueppel-like factor 9". Gene KLF9 is also known as gene BTEB or gene BTEB1, and protein KLF9 is also known as BTEB1 transcription factor or "GC box binding protein 1" or "basic transcription element binding protein 1" or "BTE binding protein 1". It is part of the Sp1 C2H2 type zinc finger transcription factor family. It is typically described in et al. (2012) Proc. Natl. Acad. Science USA 109: 10903-10908. The human KLF9 protein sequence is typically cited by UniProt accession number Q13886.
[0057] In the context of the present invention, the UniProt references cited above are those available as of June 19, 2018.
[0058] Cell models
[0059] Method for preparing cell models
[0060] A subject of the present invention is an in vitro method for preparing a cell model, comprising at least one step of culturing fibroblasts of the dermal-subcutaneous junction.
[0061] Preferably, the dermal-subcutaneous junction fibroblasts are identified according to the identification method defined in the section "dermal-subcutaneous junction fibroblasts".
[0062] The fibroblasts are particularly present at a density of 700 to 5000 cells / cm 2 , preferably at 1000 to 4000 cells / cm 2 Vaccination.
[0063] Furthermore, the culture supports used are 2D culture supports familiar to the person skilled in the art, such as treated plastic culture dishes or multi-well culture plates, such as 24-well or 96-well microplates, for cell culture.
[0064] Advantageously, the fibroblasts are cultured for 24 h to 72 h after reaching at least 80% confluence, preferably for 48 h after reaching at least 80% confluence, even better still for 48 h after reaching confluence.
[0065] "Confluent" herein means that the cell layer is cultured as a monolayer on a suitable support with no gaps between each adherent cell and can be observed, for example, with the naked eye or a microscope.
[0066] The dermal-subcutaneous junction fibroblasts are preferably cultured in a culture medium that allows their expansion, in particular a culture medium selected from MEM, DMEM, DMEM / F12, and / or FGM, which culture medium further comprises at least 5% fetal calf serum (FCS), glutamine, sodium pyruvate, non-essential amino acids and optionally antibiotics and / or antifungals.
[0067] In a specific embodiment, the dermal-subcutaneous junction fibroblasts are cultured in MEM medium, which further comprises 10% fetal calf serum (FCS), glutamine, sodium pyruvate, non-essential amino acids, and optionally antibiotics and / or antifungals.
[0068] "Expand" herein means the proliferation or multiplication of cells.
[0069] In a first embodiment, the in vitro method for preparing the cell model according to the present invention further comprises a step of centrifuging the fibroblasts obtained at the end of the culturing step.
[0070] In a second embodiment, the in vitro method for preparing the cell model according to the invention does not comprise a step of centrifuging the fibroblasts obtained at the end of the culturing step.
[0071] In a specific embodiment, the method for preparing the cell model according to the present invention does not include the step of culturing fibroblasts other than fibroblasts of the dermal-subcutaneous junction, in particular it does not include the step of culturing papillary and / or reticular fibroblasts.
[0072] In another embodiment, the step of culturing dermal-subcutaneous junction fibroblasts in the preparation method according to the present invention is carried out from a biological sample containing an amount of dermal-subcutaneous junction fibroblasts of at least 60%, preferably at least 80%, relative to the total amount of cells present in said biological sample.
[0073] Even more preferably, the step of culturing dermal-subcutaneous junction fibroblasts in the preparation method according to the invention is carried out from a biological sample containing an amount of dermal-subcutaneous junction fibroblasts of between 60% and 95%, even better still between 80% and 95%, relative to the total amount of cells present in said biological sample.
[0074] The biological sample may be an in vitro culture of dermal fibroblasts or a mixture of dermal fibroblasts, a sample derived from a skin biopsy, or a sample derived from dermis or skin equivalent obtained in vitro.
[0075] Preferably, a biological sample of dermal fibroblasts is isolated from non-defatted human skin at the connective trabeculae present at the dermal-subcutaneous junction.The connective trabeculae are removed using forceps and scissors.
[0076] Cell models
[0077] The present invention also relates to a cell model obtainable according to the method mentioned above in the section "Method for preparing a cell model".
[0078] Preferably, the cell model according to the present invention comprises fibroblasts at the dermal-subcutaneous junction, with respect to these fibroblasts:
[0079] 1) (i) the level of expression product of gene UCP2 is decreased relative to the control level,
[0080] (ii) the level of the expression product of the gene ACAN increases relative to the control level,
[0081] (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and / or
[0082] (iv) the level of the expression product of the gene COL11A1 increases relative to the control level,
[0083] as well as
[0084] 2) the level of the expression product of the gene KLF9 is increased relative to the control level;
[0085] The control levels of 1(i), 1(ii), 1(iii) and 1(iv) are preferably the levels of the expression products of the genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, respectively, and the control level of 2) is preferably the level of the expression product of the gene KLF9 in dermal fibroblasts known to be reticular fibroblasts.
[0086] The definitions of the terms "control level," "dermal fibroblasts known to be papillary or reticular dermal fibroblasts," "expression product of gene X," "dermal fibroblasts," "papillary fibroblasts," "reticular fibroblasts," "gene UCP2," "gene ACAN," "gene FGF9," "gene COL11A1," and "gene KLF9" mentioned above in the "fibroblasts at the dermal-subdermal junction" section will be used again.
[0087] When the method according to the invention further comprises the step of centrifuging the fibroblasts obtained at the end of said culturing step, the cell model is in the form of spheroids.
[0088] "Spheroid" herein means a group of cells with an irregular and disorganized shape.
[0089] In a specific embodiment, the cell model according to the present invention is composed of fibroblasts from the dermal-subcutaneous junction, and for these fibroblasts:
[0090] 1) (i) the level of expression product of gene UCP2 is decreased relative to the control level,
[0091] (ii) the level of the expression product of the gene ACAN increases relative to the control level,
[0092] (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and / or
[0093] (iv) the level of the expression product of the gene COL11A1 increases relative to the control level,
[0094] as well as
[0095] 2) the level of the expression product of the gene KLF9 is increased relative to the control level;
[0096] The control levels of 1(i), 1(ii), 1(iii) and 1(iv) are preferably the levels of the expression products of the genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, respectively, and the control level of 2) is preferably the level of the expression product of the gene KLF9 in dermal fibroblasts known to be reticular fibroblasts.
[0097] In another particular embodiment, dermal-subdermal junction fibroblasts are present in the cell model according to the invention in an amount of at least 60%, preferably at least 80%, relative to the total amount of cells present in said cell model.
[0098] Even more preferably, dermal-subdermal junction fibroblasts are present in the cell model according to the invention in an amount of between 60% and 95%, even better still between 80% and 95%, relative to the total amount of cells present in said cell model.
[0099] Organizational Model
[0100] Method for preparing tissue models
[0101] The present invention also relates to an in vitro method for preparing a tissue model, comprising at least one step of culturing fibroblasts of the dermal-subdermal junction on a collagen sponge.
[0102] The term "collagen sponge" is also well known to those skilled in the art and refers to a biopolymer based on collagen.
[0103] According to the present invention, collagen may be any type of collagen of any origin, preferably of animal origin, in particular of bovine origin. In this respect, reference will be made to the different types of collagen mentioned in the reviews of Van der Rest and Garonne, 1990, Biochem., Vol. 72, 473-484 or 1991, Faseb Journal, Vol. 5, 2814-2823.
[0104] Thus, according to the present invention, the collagen is preferably selected from type I, III or V fibrillar collagen; even better, the collagen used in the context of the present invention is type I collagen.
[0105] Examples of collagen sponges that may be mentioned are those sold by BASF Beauty Care or Symatese Biomateriaux. sponge.
[0106] The fibroblasts are preferably seeded at 125,000 to 500,000 cells, preferably 200,000 to 300,000 cells.
[0107] Preferably, the fibroblasts are cultured for 10 to 20 days, particularly preferably for 14 days.
[0108] Advantageously, the tissue model according to the present invention is not in the form of a collagen lattice. The term "collagen lattice" is well known in the art (Bell et al., 1979, Proc Natl Acad Sci USA, Vol. 76, No. 3, pp. 1274-1278) and refers to a dermis equivalent model that has been known and used for decades.
[0109] The dermal-subcutaneous junction fibroblasts are preferably cultured in a culture medium that allows their expansion, in particular a culture medium selected from MEM, DMEM, DMEM / F12, and / or FGM, which culture medium further comprises at least 5% fetal calf serum (FCS), glutamine, sodium pyruvate, non-essential amino acids and optionally antibiotics and / or antifungals.
[0110] In a specific embodiment, the dermal-subcutaneous junction fibroblasts are cultured in MEM medium, which further comprises 10% fetal calf serum (FCS), glutamine, sodium pyruvate, non-essential amino acids, and optionally antibiotics and / or antifungals.
[0111] "Expand" herein means the proliferation or multiplication of cells.
[0112] In a particular embodiment, the method for preparing the tissue model according to the present invention does not include the step of culturing fibroblasts other than fibroblasts of the dermal-subcutaneous junction, in particular it does not include the step of culturing papillary and / or reticular fibroblasts.
[0113] In another embodiment, the step of culturing dermal-subcutaneous junction fibroblasts in the preparation method according to the present invention is carried out from a biological sample containing an amount of dermal-subcutaneous junction fibroblasts of at least 60%, preferably at least 80%, relative to the total amount of cells present in said biological sample.
[0114] Even more preferably, the step of culturing dermal-subcutaneous junction fibroblasts in the preparation method according to the invention is carried out from a biological sample containing an amount of dermal-subcutaneous junction fibroblasts of between 60% and 95%, even better still between 80% and 95%, relative to the total amount of cells present in said biological sample.
[0115] The biological sample may be an in vitro culture of dermal fibroblasts or a mixture of dermal fibroblasts, a sample derived from a skin biopsy, or a sample derived from dermis or skin equivalent obtained in vitro.
[0116] Preferably, a biological sample of dermal fibroblasts is isolated from non-defatted human skin at the connective trabeculae present at the dermal-subcutaneous junction.The connective trabeculae are removed using forceps and scissors.
[0117] Organizational Model
[0118] The present invention also relates to a tissue model obtainable according to the method mentioned above in the section "Method for preparing a tissue model".
[0119] Preferably, the tissue model according to the present invention comprises fibroblasts at the dermal-subcutaneous junction, with respect to these fibroblasts:
[0120] 1) (i) the level of expression product of gene UCP2 is decreased relative to the control level,
[0121] (ii) the level of the expression product of the gene ACAN increases relative to the control level,
[0122] (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and / or
[0123] (iv) the level of the expression product of the gene COL11A1 increases relative to the control level,
[0124] as well as
[0125] 2) the level of the expression product of the gene KLF9 is increased relative to the control level;
[0126] The control levels of 1(i), 1(ii), 1(iii) and 1(iv) are preferably the levels of the expression products of the genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, respectively, and the control level of 2) is preferably the level of the expression product of the gene KLF9 in dermal fibroblasts known to be reticular fibroblasts.
[0127] The definitions of the terms "control level," "dermal fibroblasts known to be papillary or reticular dermal fibroblasts," "expression product of gene X," "dermal fibroblasts," "papillary fibroblasts," "reticular fibroblasts," "gene UCP2," "gene ACAN," "gene FGF9," "gene COL11A1," and "gene KLF9" mentioned above in the "fibroblasts at the dermal-subdermal junction" section will be used again.
[0128] In a specific embodiment, the tissue model according to the present invention is composed of fibroblasts at the dermal-subcutaneous junction, and for these fibroblasts:
[0129] 1) (i) the level of expression product of gene UCP2 is decreased relative to the control level,
[0130] (ii) the level of the expression product of the gene ACAN increases relative to the control level,
[0131] (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and / or
[0132] (iv) the level of the expression product of the gene COL11A1 increases relative to the control level,
[0133] as well as
[0134] 2) the level of the expression product of the gene KLF9 is increased relative to the control level;
[0135] The control levels of 1(i), 1(ii), 1(iii) and 1(iv) are preferably the levels of the expression products of the genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, respectively, and the control level of 2) is preferably the level of the expression product of the gene KLF9 in dermal fibroblasts known to be reticular fibroblasts.
[0136] In another specific embodiment, the fibroblasts at the dermal-subcutaneous junction are present in the tissue model according to the present invention in an amount of at least 60%, preferably at least 80%, relative to the total amount of cells present in the tissue model. Even more preferably, the fibroblasts at the dermal-subcutaneous junction are present in the tissue model according to the present invention in an amount of between 60% and 95%, even better still between 80% and 95%, relative to the total amount of cells present in the tissue model.
[0137] Use and screening methods
[0138] The present invention also relates to the use of in vitro cell or tissue models as defined in the "Cell Models" and "Tissue Models" sections as a tool for screening active agents that promote the differentiation of fibroblasts of the dermal-subcutaneous junction into adipocytes, osteoblasts and / or chondroblasts.
[0139] "Fat cell" is herein meant to be a cell characterized by the accumulation of lipid droplets in the cell body, which droplets are able to fuse to form a single lipid vacuoles that occupy the entire cell volume. The presence of fat cells is usually confirmed by using lipid stains such as Oil Red (Oil Red O) or Sudan (Sudan Black).
[0140] "Osteoblasts" herein are cells whose morphology is indistinguishable from fibroblasts cultured in two dimensions. The presence of osteoblasts is usually confirmed by using staining that shows the synthesis of the extracellular matrix, which is characteristic of bone-mineralizing osteoblasts. For this purpose, stains such as alizarin are used. Alizarin has a high affinity for calcium deposits. Alizarin can also be used to measure the activity of alkaline phosphatase, an enzyme present in large quantities in these cells.
[0141] "Chondrocytes" herein means cells whose morphology is indistinguishable from the fibroblasts of two-dimensional culture. The presence of chondroblasts is usually confirmed by using a staining agent with high affinity for the extracellular matrix secreted by them. Among the staining agents commonly used, toluidine blue and safranin O can be mentioned. These staining agents have high affinity for the acidic proteoglycans present in a large number of cartilages. After fixation, safranin O dyes into orange or even red, while toluidine blue will show purple staining. Immunohistochemical labeling can also be carried out for the proteins present in a large number of this extracellular matrix. Therefore, type II collagen, type XI collagen or aggrecan can be mentioned.
[0142] The present invention also relates to a method for screening active agents that promote the differentiation of fibroblasts at the dermal-subcutaneous junction into adipocytes, osteoblasts and / or chondroblasts, the method comprising the following steps:
[0143] i. Provide a cell or tissue model as defined in the "Cell Model" and "Tissue Model" sections,
[0144] ii. contacting the model with at least one agent to be screened,
[0145] iii. qualitatively and / or quantitatively measuring the expression of at least one marker of adipocytes, osteoblasts and / or chondrocytes or one or more biological activities thereof, and then
[0146] iv. comparing the measurements performed in step iii) with those obtained in the control.
[0147] Advantageously, the control is a cell or tissue model cultured under the same conditions as those implemented in step i), but which has not received the active agent to be screened.
[0148] According to a first embodiment, the model in step i) is a cell model obtainable according to a preparation method comprising at least one step of culturing fibroblasts at the dermal-subcutaneous junction, and which is capable of qualitatively and / or quantitatively measuring the expression of at least one marker of adipocytes and / or osteoblasts or one or more biological activities thereof in step iii).
[0149] According to a second embodiment, the model in step i) is a cell model obtainable according to a preparation method comprising at least one step of culturing fibroblasts of the dermal-subcutaneous junction followed by a centrifugation step, and which is capable of qualitatively and / or quantitatively measuring the expression of at least one marker of chondrocytes or one or more biological activities thereof in step iii).
[0150] According to a third embodiment, the model in step i) is a tissue model obtainable according to a preparation method comprising at least one step of culturing dermal-subcutaneous junction fibroblasts on a collagen sponge, and which is capable of qualitatively and / or quantitatively measuring the expression of at least one marker of adipocytes and / or osteoblasts or one or more biological activities thereof in step iii).
[0151] "Qualitative and / or quantitative measurement of the expression of at least one marker of adipocytes, osteoblasts and / or chondroblasts" in this document equally means morphological features visible to the naked eye or microscopically, and also means the presence and / or expression of genes and / or proteins that are specific for a given cell type (adipocytes, osteoblasts or chondroblasts), as mentioned above in the "Methods of Use and Screening" section and in the following publications: Pittenger et al. Science 1999; Peiffer et al. Leukemia 2007; Choudhery et al. J Transl Med 2014.
[0152] By "adipocyte, osteoblast and / or chondroblast biological activity" is meant herein enzymatic activities and / or metabolite producing activities that are specific to the cell type (adipocyte, osteoblast or chondroblast), as mentioned above in the "Methods of Use and Screening" section and in the following publications: Pittenger et al. Science 1999; Peiffer et al. Leukemia 2007; Choudhery et al. J Transl Med 2014.
[0153] The advantage of such a screening method is in particular the ability to select active agents of interest in the field of skin care, in particular in the field of anti-aging.
[0154] Furthermore, the screening method according to the invention allows the identification of new active agents for preventing and / or treating signs of skin aging and in particular for preventing and / or treating aesthetic imperfections due to loss of connective tissue, such as loss of adipose tissue.
[0155] The following examples and figures are provided by way of illustration and do not limit the scope of the present invention. BRIEF DESCRIPTION OF THE DRAWINGS
[0156] Figure 1 : View of an area derived from fibroblasts with a view of the dermal-subdermal junction.
[0157] Figure 2 : It was demonstrated that in the cell model according to Example 1, fibroblasts at the dermis-subcutaneous tissue junction differentiated into adipocytes.
[0158] Figure 3 : It was demonstrated that in the cell model according to Example 1, fibroblasts at the dermis-subcutaneous tissue junction differentiated into osteoblasts.
[0159] Figure 4 : Demonstrated differentiation of fibroblasts from the dermal-subcutaneous junction into chondrocytes in the spheroid cell model according to Example 1.
[0160] Figure 5 : Demonstrated that in the tissue model according to Example 2, fibroblasts at the dermis-subcutaneous tissue junction differentiate into adipocytes.
[0161] Figure 6 : Demonstrates that fibroblasts Fp (outside the present invention), Fr (outside the present invention), and F-DHJ (according to the present invention) differentiate into adipocytes in a cell model.
[0162] Figure 7: Demonstrates that fibroblasts Fp (outside the present invention), Fr (outside the present invention), and F-DHJ (according to the present invention) differentiate into osteoblasts in a cell model.
[0163] Figure 8 : Demonstrates that fibroblasts Fp (outside the present invention), Fr (outside the present invention), and F-DHJ (according to the present invention) differentiate into chondrocytes in a cell model.
[0164] Example 1: Method for preparing a cell model derived from DHJ fibroblasts and validating the use of the cell model as a tool for screening active agents that promote the differentiation of DHJ fibroblasts into adipocytes, osteoblasts, and chondroblasts
[0165] 1) Obtaining fibroblasts from DHJ
[0166] Fibroblasts of the dermal-subcutaneous junction (F-DHJ) were isolated from undefatted human skin. Samples were collected after breast reduction for aesthetic reasons. F-DHJ were isolated from connective trabeculae present at the dermal-subcutaneous junction. The connective trabeculae were removed with forceps and scissors. (See Figure 1 )
[0167] After pulverization, the dermal fragments were digested with type II collagenase 0.2% (Gibco) at 37°C.
[0168] The cells were then expanded in MEM medium - 10% fetal bovine serum supplemented with glutamine, sodium pyruvate, non-essential amino acids, penicillin, streptomycin and amphotericin B in a humidified atmosphere at 37°C and 5% CO2.
[0169] 2) Methods for identifying DHJ fibroblasts (verification of cell phenotype by RT-qPCR)
[0170] After fibroblast expansion (between 7 and 10 population doublings), mRNA was extracted on QIAgen columns according to the instructions provided by the supplier.
[0171] Probes considered differentially expressed had to have a fold change >2 for a p-value < 0.05.
[0172] The molecular signature of the cells was verified as follows. Thus, F-DHJ cells will display relative expression levels of ACAN, Col11a1, FGF9, UCP2, and KLF9, which are consistent with those summarized in the table below.
[0173] Table 1
[0174]
[0175]
[0176]
[0177] Fp: papillary fibroblast, Fr: reticular fibroblast, FDHJ: dermal-hypodermal junction fibroblast
[0178]
[0179] Primer table for RT-qPCR validation (QIAgen-quantitech primer assay)
[0180]
[0181] 3) Method for preparing the cell model according to the present invention
[0182] a. 2D cell models
[0183] Fibroblasts from the dermal-subcutaneous junction were cultured at a density of 1400 cells / cm in a humidified atmosphere at 37°C and 5% CO2. 2 The cells were seeded in a Petri dish in MEM medium supplemented with 10% fetal bovine serum (FBS) containing glutamine, sodium pyruvate, nonessential amino acids, penicillin, streptomycin, and amphotericin B. After reaching confluence, the dermal-subcutaneous junction fibroblasts were cultured for 48 hours.
[0184] At the end of this method, a cell model according to the invention is obtained.
[0185] b. Spheroid cell models
[0186] Fibroblasts from the dermal-subcutaneous junction were cultured at a density of 1400 cells / cm in a humidified atmosphere at 37°C and 5% CO2. 2 The cells were seeded in a Petri dish in MEM medium supplemented with 10% fetal bovine serum (FBS) containing glutamine, sodium pyruvate, nonessential amino acids, penicillin, streptomycin, and amphotericin B. After reaching confluence, the dermal-subcutaneous junction fibroblasts were cultured for 48 hours.
[0187] 48 hours after reaching confluence, spheroids were formed after centrifugation of 100 000 DHJ cells.
[0188] At the end of this method, a cell model according to the invention is obtained in the form of a spheroid.
[0189] 4) Validation of the use of the cell model according to the present invention as a tool for screening active agents that:
[0190] a. Promotes DHJ fibroblast differentiation into adipocytes
[0191] To validate the use of the cell model generated in paragraph 3) a. as a tool for screening active agents that promote the differentiation of F-DHJ into adipocytes, a positive control consisting of a mixture of active agents containing indomethacin, IBMX and dexamethasone, which are known for their activity in promoting the differentiation of fibroblasts into adipocytes (Peiffer et al., Leukemia 2007 Apr;21(4):714-24), was used.
[0192] Therefore, the medium in point 3) a. was replaced by a mixture of the following composition: 60 μM indomethacin / 0.5 mM IBMX / 10 -6 M dexamethasone, diluted in DMEM / 20% fetal bovine serum. Cells were cultured for 3 weeks in the presence of the differentiation induction cocktail. The culture medium was refreshed 3 times per week.
[0193] At the end of the 3-week induction, the cells were fixed in 4% paraformaldehyde and the cells were examined under a microscope for differentiation into adipocytes. Highly refractile spheres were observed within the cells. Oil red O staining was also performed, which is known to stain lipid droplets present in adipocytes red. (See Figure 2 )
[0194] Conclusion: Differentiation of DHJ fibroblasts into adipocytes was observed; therefore, this model can be used as a tool to screen for agents that promote differentiation of DHJ fibroblasts into adipocytes.
[0195] b. Promotes differentiation of DHJ fibroblasts into osteoblasts
[0196] To validate the use of the cell model generated in paragraph 3) a. as a tool for screening active agents that promote the differentiation of F-DHJ into osteoblasts, a positive control was used consisting of a mixture of active agents containing 2β-glycerophosphate, ascorbic acid 2-phosphate and dexamethasone, which are known for their activity in promoting the differentiation of fibroblasts into osteoblasts (Peiffer et al., Leukemia 2007 Apr;21(4):714-24).
[0197] Therefore, the medium in point 3) a. was replaced by a mixture consisting of: 2 mM 2β-glycerophosphate, 0.15 mM ascorbic acid 2-phosphate, 10 -7 The cells were cultured in the presence of the differentiation induction cocktail (M dexamethasone and 10% fetal bovine serum) for 3 weeks, with the culture medium refreshed 3 times per week.
[0198] At the end of the 3-week induction period, cell culture was stopped by fixation in 4% paraformaldehyde. Cells that were differentiated toward the osteoblastic spectrum were detected by alizarin staining. This product stains the calcified extracellular matrix red. (See Figure 3 )
[0199] Conclusion: Differentiation of DHJ fibroblasts into osteoblasts was observed; therefore, this model can be used as a tool to screen for agents that promote differentiation of DHJ fibroblasts into osteoblasts.
[0200] c. Promotes DHJ fibroblast differentiation into chondrocytes
[0201] To validate the use of the cell model generated in paragraph 3) b. as a tool for screening active agents that promote the differentiation of F-DHJ into chondrocytes, a positive control consisting of a mixture of active agents containing insulin, transferrin, sodium selenite, linoleic acid, oleic acid, bovine serum albumin, sodium pyruvate, ascorbic acid 2-phosphate and dexamethasone was used, which are known for their activity in promoting the differentiation of fibroblasts into chondrocytes (Mesenchymal stem cells and hematopoietic stem cells form a unique bone marrow niche, Méndez-Ferrer S, Michurina TV, Ferraro F, Mazloom AR, Macarthur BD, Lira SA, Scadden DT, Ma′ayan A, Enikolopov GN, Frenette PS, Nature. 2010 Aug 12;466(7308):829-34. doi:10.1038 / nature09262).
[0202] 24 hours after spheroid formation, the medium from point 3) b. was replaced with an induction mixture consisting of 0.5 μg / ml insulin, 0.5 μg / ml transferrin, 0.5 ng / ml sodium selenite, 6.25 μg / ml linoleic acid, 6.25 μg / ml oleic acid, 1.25 mg / ml bovine serum albumin, 1 mmol / l sodium pyruvate, 0.17 mmol / l ascorbic acid 2-phosphate, 0.1 μmol / l dexamethasone, 0.35 mmol / l proline, and 0.01 μg / ml TGF-β. The medium was refreshed three times a week for two weeks.
[0203] After OCT application, the culture was stopped by freezing the spheroids. The spheroids were then cut at 5 μm using a microtome. Differentiation of F-DHJ into chondrogenic cells was confirmed by staining with toluidine blue supplemented with safranin O staining (see Figure 4 ).
[0204] Conclusion: Differentiation of DHJ fibroblasts into chondrocytes was observed; therefore, this model can be used as a tool to screen for agents that promote differentiation of DHJ fibroblasts into chondrocytes.
[0205] Example 2: Method for preparing a tissue model from DHJ fibroblasts on a collagen sponge and validating the use of the tissue model as a tool for screening active agents that promote the differentiation of DHJ fibroblasts into adipocytes
[0206] 1) Obtaining fibroblasts from DHJ (according to Example 1)
[0207] 2) Method for identifying DHJ fibroblasts (verification of cell phenotype by RT-qPCR) (according to Example 1)
[0208] 3) Method for preparing the tissue model according to the present invention
[0209] The cells of the dermal-subcutaneous junction were seeded at 250,000 cells / sponge (Symatese Biomaterials) in MEM medium supplemented with 10% fetal calf serum, glutamine, sodium pyruvate, non-essential amino acids, penicillin, streptomycin, and amphotericin B, at 37°C and 5% CO2 in a humidified atmosphere and maintained in culture for 14 days.
[0210] At the end of this method, a tissue model according to the invention is obtained.
[0211] 4) Validation of the use of the tissue model according to the present invention as a tool for screening active agents:
[0212] To validate the use of the tissue model generated in paragraph 3) as a tool for screening active agents that promote the differentiation of F-DHJ into adipocytes, a positive control consisting of a mixture of active agents containing indomethacin, IBMX and dexamethasone, which are known for their activity in promoting the differentiation of fibroblasts into adipocytes (Peiffer et al., Leukemia 2007 Apr;21(4):714-24), was used.
[0213] Therefore, the culture medium in point 3) was replaced by a mixture consisting of: 60 μM indomethacin / 0.5 mM IBMX / 10 - 6 M dexamethasone, diluted in DMEM / 20% fetal bovine serum. Maintain differentiation induction for 3 weeks. Refresh the culture medium 3 times per week.
[0214] At the end of the 3-week induction, the cell culture was stopped by fixation in 4% paraformaldehyde. After staining with Oil Red O (which is known to stain lipid droplets present in adipocytes red), cells that were differentiated toward adipocytes were examined under a microscope. (See Figure 5 )
[0215] Conclusion: Differentiation of DHJ fibroblasts into adipocytes was observed; therefore, this model can be used as a tool to screen for agents that promote differentiation of DHJ fibroblasts into adipocytes.
[0216] Example 3: Comparison outside the present invention: Tissue model on collagen lattice obtained from DHJ fibroblasts
[0217] The lattice was prepared according to a previously published protocol (Asselineau et al. - Exp Cell res [Experimental Cell Research], 1985). 6 F-DHJ fibroblasts were included in a bovine type I collagen solution (Symatèse Biomateriaux).
[0218] To investigate the sensitivity of the tissue model on the lattice (outside the present invention), in the context of implementing the tissue model as a tool for screening active agents that promote the differentiation of DHJ fibroblasts into adipocytes, as described for Examples 1), 4)a. and 2), 4), a positive control consisting of a mixture of indomethacin, IBMX and dexamethasone was used, which is known for its activity in promoting the differentiation of fibroblasts into adipocytes (Peiffer et al. Leukemia 2007 Apr;21(4):714-24).
[0219] Therefore, after 4 days of lattice organization and contraction, the culture medium was replaced with an induction mixture consisting of: 60 μM indomethacin / 0.5 mM IBMX / 10 -6 M dexamethasone, diluted in DMEM / 20% fetal bovine serum. Maintain differentiation induction for 3 weeks. Refresh the culture medium 3 times per week.
[0220] At the end of the 3-week induction period, cell culture was terminated by freezing the lattices after application of OCT. The lattices were then sectioned at 5 μm using a microtome. Oil Red O staining was used to demonstrate the differentiation of F-DHJ cells into adipocytes. Under these induction conditions, F-DHJ cells did not differentiate into adipocytes. It was not possible to demonstrate adipocyte staining.
[0221] Conclusion: No differentiation of DHJ fibroblasts into adipocytes was observed; therefore, this model is not sensitive enough to be used as a tool to screen for agents that promote the differentiation of DHJ fibroblasts into adipocytes.
[0222] Example 4: Comparison outside the present invention: Cell models derived from papillary or reticulofibroblasts
[0223] 1) Methods for preparing cell models other than those of the present invention
[0224] The method performed was the same as that described in point 3) of Example 1 above, in which the DHJ fibroblasts were replaced by papillary fibroblasts or reticulofibroblasts.
[0225] Thus, at the end of this method, a cell model other than the present invention obtained from papillary fibroblasts and a cell model other than the present invention obtained from reticulofibroblasts are given.
[0226] 2) To investigate the use of cell models other than those of the present invention as tools for screening active agents that:
[0227] a. Promotes the differentiation of papillary or reticular fibroblasts into adipocytes
[0228] The method implemented is the same as that described in point 4) a. of Example 1.
[0229] Cells that are on the adipocyte differentiation spectrum were examined microscopically. In a small number of cells in established cultures of papillary and reticulofibroblasts, small refractile spheres indicating the presence of lipid vacuoles were observed (see Figure 6 Counting staining with Oil Red O confirmed that these vacuoles were lipid in nature.
[0230] Conclusion: Very little differentiation of papillary or reticular fibroblasts into adipocytes was observed; therefore, cell models derived from papillary or reticular fibroblasts are not sensitive enough to be used as a screening tool for agents that promote differentiation of these fibroblasts into adipocytes.
[0231] b. Promotes the differentiation of papillary or reticular fibroblasts into osteoblasts
[0232] The method implemented is the same as that described in point 4) b. of Example 1.
[0233] Cells that are on the osteoblast differentiation spectrum were detected by alizarin staining. This product stains the calcified extracellular matrix red. In the case of cell models derived from papillary fibroblasts, no red staining was observed, and therefore no calcified extracellular matrix was present. In the case of cell models derived from reticular fibroblasts, very small traces of red staining were observed, indicating that the extracellular matrix was calcified (see Figure 7 ). Therefore, the tendency of papillary and reticular fibroblasts to differentiate into osteoblasts is very weak.
[0234] Conclusion: Very little differentiation of papillary or reticulofibroblasts into osteoblasts was observed; therefore, cell models derived from papillary or reticulofibroblasts are not sensitive enough to be used as a screening tool for agents that promote differentiation of these fibroblasts into osteoblasts.
[0235] c. Promotes the differentiation of papillary or reticular fibroblasts into chondrocytes
[0236] The method implemented is the same as the method described in point 4) c. of Example 1.
[0237] Toluidine blue staining supplemented with safranin O staining was used to demonstrate the differentiation of papillary or reticulofibroblasts into chondrocytes. In the case of cell models derived from papillary and reticulofibroblasts, light blue and light red staining were observed, whereas in the case of cell models derived from fibroblasts of the DHJ, dark blue staining was observed in the periphery and dark red staining was observed. (See Figure 8 )
[0238] Conclusion: Very little differentiation of papillary or reticulofibroblasts into chondrocytes was observed; therefore, cell models derived from papillary or reticulofibroblasts are not sensitive enough to be used as a screening tool for agents that promote differentiation of these fibroblasts into chondrocytes.
[0239] The table below summarizes the potential of the tested fibroblast subsets (Fp, Fr or F-DHJ) to differentiate into adipocytes, osteoblasts and chondroblasts.
[0240] Table 2
[0241]
Claims
1. An in vitro method for preparing a cell model, the method comprising a step of identifying dermal fibroblasts as dermal-subcutaneous combined fibroblasts and at least one step of culturing the dermal-subcutaneous combined fibroblasts identified in the identification step, the identification step being prior to the culturing step and comprising: a) providing a biological sample comprising at least one dermal fibroblast, wherein the biological sample is isolated from non-defatted human skin at connective trabeculae present at the dermal-subdermal junction, b) measuring the levels of expression products of genes UCP2, ACAN, FGF9 and COL11A1, and measuring the level of expression product of gene KLF9 in the biological sample provided in step a), c) identifying the dermal fibroblasts in step a) as dermal-subdermal junction fibroblasts when: 1) (i) the level of the expression product of the gene UCP2 is reduced relative to the control level, (ii) the level of the expression product of the gene ACAN increases relative to the control level, (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and (iv) the level of the expression product of the gene COL11A1 increases relative to the control level, as well as 2) The level of the expression product of the gene KLF9 increases relative to the control level, Wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) are respectively the levels of the expression products of genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, and the control level of 2) is the level of the expression product of gene KLF9 in dermal fibroblasts known to be reticular fibroblasts.
2. The method of claim 1, wherein the fibroblasts are cultured for 24 h to 72 h after reaching at least 80% confluence.
3. The method of claim 2, wherein the fibroblasts are cultured for 48 h after reaching at least 80% confluence.
4. The method according to claim 1 or 2, further comprising the step of centrifuging the fibroblasts obtained at the end of the culturing step.
5. An in vitro method for preparing a tissue model, the method comprising a step of identifying dermal fibroblasts as dermal-subcutaneous combined fibroblasts and at least one step of culturing the dermal-subcutaneous combined fibroblasts identified in the identification step, the identification step being prior to the culturing step and comprising: a) providing a biological sample comprising at least one dermal fibroblast, wherein the biological sample is isolated from non-defatted human skin at connective trabeculae present at the dermal-subdermal junction, b) measuring the levels of expression products of genes UCP2, ACAN, FGF9 and COL11A1, and measuring the level of expression product of gene KLF9 in the biological sample provided in step a), c) identifying the dermal fibroblasts in step a) as dermal-subdermal junction fibroblasts when: 1) (i) the level of the expression product of the gene UCP2 is reduced relative to the control level, (ii) the level of the expression product of the gene ACAN increases relative to the control level, (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and (iv) the level of the expression product of the gene COL11A1 increases relative to the control level, as well as 2) The level of the expression product of the gene KLF9 increases relative to the control level, Wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) are respectively the levels of the expression products of genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, and the control level of 2) is the level of the expression product of gene KLF9 in dermal fibroblasts known to be reticular fibroblasts. The method of claim 5 , wherein the fibroblasts are cultured for 10 to 20 days.
7. The method of claim 6, wherein the fibroblasts are cultured for 14 days.
8. An in vitro cell model, obtained according to the method of any one of claims 1 to 3, comprising dermal-subcutaneous combined fibroblasts, and for the fibroblasts: 1) (i) the level of the expression product of the gene UCP2 is reduced relative to the control level, (ii) the level of the expression product of the gene ACAN increases relative to the control level, (iii) the level of the expression product of the gene FGF9 is increased relative to the control level, and (iv) the level of the expression product of the gene COL11A1 increases relative to the control level, as well as 2) The level of the expression product of the gene KLF9 increases relative to the control level, Wherein the control levels of 1(i), 1(ii), 1(iii) and 1(iv) are respectively the levels of the expression products of genes UCP2, ACAN, FGF9 and COL11A1 in dermal fibroblasts known to be papillary fibroblasts, and the control level of 2) is the level of the expression product of gene KLF9 in dermal fibroblasts known to be reticular fibroblasts.
9. Use of the in vitro cell model as claimed in claim 8 as a tool for screening active agents that promote the differentiation of fibroblasts of the dermal-subcutaneous junction into adipocytes, osteoblasts and / or chondroblasts.
10. A method for screening an active agent that promotes differentiation of fibroblasts at the dermal-subcutaneous junction into adipocytes, osteoblasts and / or chondroblasts, the method comprising the following steps: i. Providing a cell model as claimed in claim 8, ii. contacting the model with at least one agent to be screened, iii. qualitatively and / or quantitatively measuring the expression of at least one marker of adipocytes, osteoblasts and / or chondrocytes or one or more biological activities thereof, and then iv. comparing the measurements performed in step iii) with those obtained in the control.
Citation Information
Patent Citations
Separation culture method for cartilage stem cells
CN102399745A
Molecular signatures of three sub-populations of dermal fibroblasts and dermal equivalent comprising one of these sub-populations
CN111164223A
Soft tissue repair allografts and methods for preparing same
US20140276957A1
Method for identifying molecular markers of children's skin
US20150285787A1
Cell-free dermal tissue implant
WO2013137664A1
